Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis

Kai Qian; Jie Xu; Heng Wan; Fangyong Fu; Jingbo Lu; Zhiqi Lin; Zhengjun Liu; Hao Liu

doi:10.1016/j.gene.2015.06.014

Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis

Gene. 2015 Sep 15;569(2):173-81. doi: 10.1016/j.gene.2015.06.014. Epub 2015 Jun 10.

Authors

Kai Qian¹, Jie Xu², Heng Wan¹, Fangyong Fu¹, Jingbo Lu¹, Zhiqi Lin¹, Zhengjun Liu¹, Hao Liu³

Affiliations

¹ Department of Vascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
² Department of Neurology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
³ Department of Vascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Electronic address: specificgz@163.com.

PMID: 26071134
DOI: 10.1016/j.gene.2015.06.014

Abstract

Background: Reported studies have showed that Thrombin Activatable Fibrinolysis Inhibitor (TAFI) may be associated with an increased risk of venous thromboembolism. But the relation of VT with TAFI gene SNPs could not be clearly demonstrated. Thus, we conducted a meta-analysis to analyze the associations between three TAFI variants -438G/A, 505G/A and 1040C/T and the risk of venous thrombosis.

Methods: We carried out a systematic search to obtain all the eligible studies published before 30th October 2014. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were computed to assess the association.

Results: 13 eligible studies were enrolled including 2321 patients and 2464 controls. There was a significant association between 505G/A and the risk of VTD under all models except recessive model (G vs. A: OR=1.13, 95% CI: 1.02, 1.26; GG vs. AA:OR=1.47, 95% CI: 1.14, 1.88; GA vs. AA: OR=1.36, 95% CI: 1.06, 1.73; GG+GA vs. AA: OR=1.41, 95% CI: 1.12, 1.77). Similarly, obvious relationship was observed in subgroup analyses in light of type of disease and ethnicity. Likewise, for 1040C/T variant, significant associations were identified under homozygote, heterozygote and dominant models (CC vs. TT: OR=1.65, 95% CI: 1.06, 2.59; CT vs. TT: OR=1.55, 95% CI: 1.19, 2.03; CC+CT vs. TT: OR=1.55, 95% CI: 1.20, 2.00). Sub-analysis presented significant associations in non-CVT and non-Asian group under homozygote, heterozygote, and dominant models and CVT group in recessive model.

Conclusion: This meta-analysis showed that -438G/A variant was not associated with the incidence of venous thrombosis. But in non-Asian populations, G allele and GG genotype of 505G/A may increase the risk of venous thrombosis diseases. GG genotype of 505G/A and one C carrier (CC and CT) of 1040C/T gave rise to the development of venous thrombosis diseases except CVT. Additionally, the heterozygote CT may be a potential contributing factor of gene effect in venous thrombosis.

Keywords: Meta-analysis; Polymorphisms; Thrombin activatable fibrinolysis inhibitor; Venous thrombosis.

Publication types

Meta-Analysis
Review

MeSH terms

Carboxypeptidase B2 / genetics*
Genetic Predisposition to Disease
Humans
Polymorphism, Single Nucleotide*
Pulmonary Embolism / genetics
Racial Groups / genetics
Venous Thrombosis / genetics*
Venous Thrombosis / physiopathology

Substances

Carboxypeptidase B2